2 Matching Annotations
  1. Last 7 days
    1. F8.I.2

      Case#: Female, 75 (age when studied in 1975)

      Disease: Glazmann's Thrombasthenia Like Syndrome

      CasePresentingHPOs: HP:0001873, HP:0006298

      Thrombocytopenia, Prolonged bleeding after dental extraction

      CaseNotHPOs: NA

      FamilyInfo: Pedigree figure 1. Several affected family members.

      PlateletAgreggation:Daughter studied: Decreased PLT aggregation and diminished ATP release with the agonists ADP, collagen, and AA, with normal ristocetin agglutination

      GenotypingMethod: Genetic analysis of ITGA2B and ITGB3 genes was performed by next-generation sequencing (NGS). Sanger sequencing used to confirm variants.

      From Daughter

      ClinVar: Not Found

      CAID: CA400034393

      Variant: NM_000212.3:c.2278C>T (ITGB3)

      GnomAD: Not Found

      ExpressionEvidence: Level of expression on PLT surface determined by FCM: CD41a (GPIIb/IIIa) 52%, CD61 (GPIIIa) 77%, and CD42b (GPIb) 129%. Healthy control value range: CD41a (GPIIb/IIIa) (85-115%); CD61 (GPIIIa) (80-120%); CD42b (GPIb) (70-130%).

    2. F9.II.2

      Case#: Female, 37 (age when studied)

      Disease: Glazmann's Thrombasthenia Like Syndrome

      CasePresentingHPOs: HP:0001873, HP:0000978, HP:0000225

      Thrombocytopenia, bruising susceptibility, gingival bleeding

      CaseNotHPOs: NA

      FamilyInfo: Pedigree figure 1. Several affected family members, history of thrombocytopenia.

      PlateletAgreggation:Sister studied: Decreased PLT aggregation and diminished ATP release with the agonists ADP, collagen, and AA, with normal ristocetin agglutination

      GenotypingMethod: Genetic analysis of ITGA2B and ITGB3 genes was performed by next-generation sequencing (NGS). Sanger sequencing used to confirm variants.

      ClinVar: Not Found

      CAID: CA400034393

      Variant: NM_000212.3:c.2278C>T (ITGB3)

      GnomAD: Not Found

      ExpressionEvidence: Level of expression on PLT surface determined by FCM: CD41a (GPIIb/IIIa) 73%, CD61 (GPIIIa) 74%, and CD42b (GPIb) 111%. Healthy control value range: CD41a (GPIIb/IIIa) (85-115%); CD61 (GPIIIa) (80-120%); CD42b (GPIb) (70-130%).